U.S. retail sales rebounded marginally in February as consumers pulled back on discretionary spending, reinforcing the ...

The S&P 500 (^GSPC) has entered correction, falling 10% from its February all-time highs as political uncertainty has driven ...

A surge in lease rates for the precious metal has become the latest sign of alarm, with anxiety building over the impact of ...

This marks the tenth ABS transaction sponsored by BHG since the start of its securitization program in 2020, and the second to be collateralized by 100% consumer loans originated by Pinnacle Bank and ...

Ulta Beauty (NASDAQ:ULTA – Get Free Report) had its price target lowered by BMO Capital Markets from $467.00 to $404.00 in a ...

BMO Capital Markets assumed coverage on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a research note issued to investors on Wednesday, MarketBeat Ratings reports. The brokerage ...

BMO Capital Markets initiated coverage on Dyne Therapeutics (DYN, Financials) with an Outperform rating and a $50 price target, suggesting a strong upside from the company's current share price of ...

On Thursday, BMO Capital Markets sustained their Market Perform rating on Casey’s General Stores (NASDAQ:CASY), with a steady price target of $450.00. The convenience store chain, currently ...

BMO Capital Markets initiated coverage on Dyne Therapeutics (DYN, Financials) with an Outperform rating and a $50 price target, suggesting a strong upside from the company's current share price of $12 ...

ECN Capital Corp. (TSX: ECN) ("ECN Capital” or the "Company”) today announced that it has entered into an agreement with a syndicate of underwriters (the "Underwriters”) led by CIBC Capital Markets, ...

On Tuesday, BMO Capital Markets began coverage of Avidity Biosciences (NASDAQ:RNA) shares, assigning an Outperform rating and setting a price target of $72.00. Currently trading at $29.58, the stock ...